Pharming Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Pharming Group NV
PHAR Stock  USD 9.36  0.62  7.09%   
Pharming Group financial statements provide useful quarterly and yearly information to potential Pharming Group NV investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pharming Group financial statements helps investors assess Pharming Group's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pharming Group's valuation are summarized below:
Gross Profit
188.1 M
Profit Margin
(0.06)
Market Capitalization
592.9 M
Enterprise Value Revenue
1.8815
Revenue
285.7 M
There are over one hundred nineteen available trending fundamental ratios for Pharming Group NV, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check out Pharming Group's recent fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 12/11/2024, Market Cap is likely to grow to about 980.3 M. Also, Enterprise Value is likely to grow to about 1.1 B

Pharming Group Total Revenue

257.58 Million

Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.7 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 6.5 M, as well as many indicators such as Price To Sales Ratio of 3.62, Dividend Yield of 0.0 or PTB Ratio of 3.92. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Check out the analysis of Pharming Group Correlation against competitors.

Pharming Group Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets486 M462.9 M219.6 M
Slightly volatile
Short and Long Term Debt Total180.1 M171.5 M78.8 M
Slightly volatile
Other Current Liabilities54.4 M51.8 M26.6 M
Slightly volatile
Total Current Liabilities46.5 M78 M48 M
Slightly volatile
Property Plant And Equipment Net35.1 M33.5 M16.9 M
Slightly volatile
Accounts Payable7.9 M14.5 M6.4 M
Slightly volatile
Cash71.7 M61.7 M75.8 M
Slightly volatile
Non Current Assets Total153.8 M146.5 M81.6 M
Slightly volatile
Cash And Short Term Investments224.1 M213.4 M96.5 M
Slightly volatile
Net Receivables33.7 M32.1 M13.2 M
Slightly volatile
Common Stock Shares Outstanding689.9 M657 M126.3 M
Slightly volatile
Liabilities And Stockholders Equity486 M462.9 M219.6 M
Slightly volatile
Non Current Liabilities Total174.4 M166.1 M78.5 M
Slightly volatile
Inventory59.6 M56.8 M22.7 M
Slightly volatile
Other Current Assets14.4 M13.8 M3.8 M
Slightly volatile
Other Stockholder Equity355.2 M479.2 M348.9 M
Slightly volatile
Total Liabilities256.3 M244.1 M128.9 M
Slightly volatile
Total Current Assets332.2 M316.3 M138 M
Slightly volatile
Short Term Debt5.2 M5.4 M11.9 M
Pretty Stable
Intangible Assets43.1 M71.3 M42.8 M
Slightly volatile
Common Stock6.6 M6.9 M10.9 M
Slightly volatile
Other Liabilities124.8 K131.4 K19.3 M
Slightly volatile
Capital Lease Obligations34.8 M33.1 M9.3 M
Slightly volatile
Deferred Long Term Liabilities227.4 K239.4 K2.7 M
Slightly volatile
Net Invested Capital258.8 M357.2 M173.4 M
Slightly volatile
Short and Long Term Debt1.7 M1.8 M17.7 M
Slightly volatile
Non Current Liabilities Other124.8 K131.4 K18.4 M
Slightly volatile
Net Working Capital134.2 M238.4 M79.7 M
Slightly volatile
Property Plant Equipment47.3 M45 M17.8 M
Slightly volatile
Capital Stock8.2 M7.7 M7.3 M
Slightly volatile
Long Term Investments8.8 M10.4 M6.6 M
Slightly volatile
Property Plant And Equipment Gross44.8 M60.4 M34.6 M
Slightly volatile

Pharming Group Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense6.4 M6 M6.2 M
Slightly volatile
Selling And Marketing Expenses6.5 M6.8 M23 M
Slightly volatile
Total Revenue257.6 M245.3 M110.7 M
Slightly volatile
Other Operating Expenses263.2 M250.7 M101.3 M
Slightly volatile
Research Development72.4 M68.9 M33.6 M
Slightly volatile
Cost Of Revenue15.2 M25.2 M13.3 M
Slightly volatile
Total Operating Expenses236.8 M225.5 M87.2 M
Slightly volatile
Selling General Administrative84.7 M80.7 M22.2 M
Slightly volatile
Interest Income2.8 M3.7 M1.4 M
Slightly volatile
Reconciled Depreciation10.7 M15.9 M6.8 M
Slightly volatile

Pharming Group Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.2 M9.3 M6.6 M
Slightly volatile
Begin Period Cash Flow217.7 M207.3 M82.4 M
Slightly volatile
Depreciation16.7 M15.9 M6.5 M
Slightly volatile
Capital Expenditures1.4 M1.5 M5.4 M
Slightly volatile
End Period Cash Flow72.2 M61.7 M76.6 M
Slightly volatile
Issuance Of Capital Stock4 M2.1 M8.5 M
Slightly volatile
Other Cashflows From Investing Activities800900980
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.623.805861.1258
Slightly volatile
Days Sales Outstanding60.2463.4059115
Slightly volatile
Average Payables6.4 M10.3 M6.9 M
Slightly volatile
Stock Based Compensation To Revenue0.03580.03770.2502
Slightly volatile
Capex To Depreciation0.08730.09191.5063
Slightly volatile
EV To Sales4.044.253458.5485
Slightly volatile
Inventory Turnover0.420.44420.7744
Pretty Stable
Days Of Inventory On Hand781822740
Very volatile
Payables Turnover1.781.73832.2342
Very volatile
Sales General And Administrative To Revenue0.310.32891.5372
Slightly volatile
Average Inventory11.8 M21.8 M16.6 M
Slightly volatile
Research And Ddevelopement To Revenue0.270.28092.3145
Slightly volatile
Capex To Revenue0.00570.0060.2085
Slightly volatile
Cash Per Share0.250.25990.2944
Slightly volatile
Days Payables Outstanding329210300
Pretty Stable
Income Quality0.91.44041.2228
Slightly volatile
Intangibles To Total Assets0.220.1540.1702
Slightly volatile
Current Ratio2.244.05732.7263
Pretty Stable
Receivables Turnover9.975.75669.1231
Very volatile
Graham Number0.260.27751.165
Slightly volatile
Debt To Equity0.890.63270.8881
Pretty Stable
Capex Per Share0.00170.00180.0153
Slightly volatile
Average Receivables29.4 M28 M12.7 M
Slightly volatile
Revenue Per Share0.310.29870.1547
Slightly volatile
Interest Debt Per Share0.170.17580.095
Slightly volatile
Debt To Assets0.220.29910.2324
Slightly volatile
Operating Cycle841885856
Pretty Stable
Days Of Payables Outstanding329210300
Pretty Stable
Long Term Debt To Capitalization0.340.38440.3718
Slightly volatile
Total Debt To Capitalization0.330.38750.3569
Slightly volatile
Debt Equity Ratio0.890.63270.8881
Pretty Stable
Quick Ratio1.783.32932.1955
Slightly volatile
Net Income Per E B T0.830.87812.7602
Very volatile
Cash Ratio1.340.79191.6806
Pretty Stable
Days Of Inventory Outstanding781822740
Very volatile
Days Of Sales Outstanding60.2463.4059115
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.081.08460.953
Slightly volatile
Fixed Asset Turnover7.77.33035.7634
Slightly volatile
Debt Ratio0.220.29910.2324
Slightly volatile
Price Sales Ratio3.623.805861.1258
Slightly volatile
Asset Turnover0.560.530.412
Slightly volatile

Pharming Group Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap980.3 M933.6 M564.9 M
Slightly volatile
Enterprise Value1.1 B1 B565.9 M
Slightly volatile

Pharming Fundamental Market Drivers

Forward Price Earnings169.4915
Cash And Short Term Investments213.4 M

Pharming Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-64.7 K-61.4 K
Total Revenue245.3 M257.6 M
Cost Of Revenue25.2 M15.2 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.33  0.31 
Research And Ddevelopement To Revenue 0.28  0.27 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.30  0.31 
Ebit Per Revenue(0.02)(0.02)

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY